Amy Paller, MD @pallerlab.bsky.social · 20/08/2026PEDISTAD study: 1,329 children with moderate-to-severe atopic dermatitis showed lower height (ages 5–<12, especially boys) and higher weight/BMI vs norms, suggesting possible growth impact. #DermSky #MedSky #atopicdermatitis 000
Amy Paller, MD @pallerlab.bsky.social · 12/07/2026Missed the latest EBRP Town Hall? Dr. Amy Paller explains ZEVASKYN®, the first FDA-approved gene-modified cell therapy for RDEB, how it works, who may be eligible, and what it could mean for people living with EB. www.ebresearch.org/62226townhal... #DermSky #MedSky #RDEB 000
Reposted by Amy Paller, MDDermatology Advisor @dermatologyadvisor.bsky.social · 15/06/2026Tralokinumab treatment for up to 1 year has no clinically relevant effect on laboratory parameters in adolescents with moderate to severe #AtopicDermatitis. #DermSky @pallerlab.bsky.social dermatologyadvisor.comTralokinumab Does Not Affect Laboratory Parameters in Adolescents With ADSimilar to adults, treatment with tralokinumab for 1 year among adolescents with AD did not significantly affect laboratory parameters. 011
Amy Paller, MD @pallerlab.bsky.social · 31/05/2026New review article now available in JAAD: "Systemic Therapies for Atopic Dermatitis" doi.org/10.1016/j.ja... The field continues to evolve rapidly, and we hope this serves as a useful resource for clinicians caring for patients with AD. #DermSky #MedSky #JAAD 000
Amy Paller, MD @pallerlab.bsky.social · 26/04/2026"Tralokinumab treatment for up to 1 year does not have any clinically relevant impact on laboratory parameters in adolescents with moderate-to-severe AD, supporting its use without required laboratory monitoring." doi.org/10.1007/s135... #DermSky #MedSky #eczema #atopicdermatitis #biologics 010
Amy Paller, MD @pallerlab.bsky.social · 30/03/2026Treatment with dupilumab for up to 2 years in infants and young children with AD demonstrated sustained efficacy with a safety profile consistent with prior studies, supporting its long-term continuous use in pediatric patients. pubmed.ncbi.nlm.nih.gov/41903092/ #DermSky #MedSky 010
Amy Paller, MD @pallerlab.bsky.social · 07/03/2026Invigorating days at the Hever castle in the UK with a team of brilliant thinkers about the future of EB treatment. We were graced by the presence of Her Royal Highness Duchess of Edinburgh and some of the most creative minds of dermatology. #dermsky #medsky @charitydebra.bsky.social 030
Reposted by Amy Paller, MDRegina Schaffer @reginaschaffer.bsky.social · 09/02/2026🚨New podcast drop! 🚨 🎙️In the latest episode of Beneath the Surface, @joelgel.bsky.social talks with Amy Paller, MD, of @feinberg.northwestern.edu about how to recognize and diagnose #measles. Check it out below 👇 www.healio.com/news/dermato... @gohealio.bsky.social @healioid.bsky.socialhealio.comHow to recognize and diagnose measles with Amy Paller, MD 153
Amy Paller, MD @pallerlab.bsky.social · 21/01/2026With the possibility that measles is on the rise, we dermatologists need to be on the lookout for children or adults coming in with the measles morbilliform rash and a history (high fever,cold symptoms,eye redness) that is suspicious for this highly contagious disease www.healio.com/news/dermato...healio.comBeneath the Surface: How to recognize and diagnose measlesMeasles, which was declared to be eliminated in 2000 in the United States, has seen a resurgence, with more than 2,000 cases documented in 2025.This is the highest number of cases since elimination wa... 010
Reposted by Amy Paller, MDRobert Lavker, Ph.D. @robertlavkerlab.bsky.social · 19/12/2025Exciting opportunity in the Peng Lab at Northwestern, focusing on stem cells, autophagy, and epithelial biology. Please share with interested candidates! postdocs.northwestern.edu/announcement... #jobSky #postdocSky #dermSky #eyeSky 032
Amy Paller, MD @pallerlab.bsky.social · 16/12/2025Excited that 3 organizations supporting Epidermal Differentiation Disorders are teaming to sponsor a special pre-SID program in Chicago that will include experts and patients. Hope to see you there. www.pachyonychia.org/2026-edd-sym... #DermSky #MedSky #raredisease #EDDs 020
Amy Paller, MD @pallerlab.bsky.social · 12/10/2025We’re excited to see our Ichthyosis community come together again! 📅 Saturday, January 17, 2026 📍 Lurie Children’s Hospital, Chicago It’s a special chance to meet others living with Ichthyosis, hear updates on ongoing research, and enjoy some fun and support together. We hope to see you there 💙 021
Amy Paller, MD @pallerlab.bsky.social · 14/08/2025An Acid-Oxidising Solution Containing Hypochlorous Acid Reduces Staphylococcus aureus and Improves Bacterial Diversity in Epidermolysis Bullosa Wounds #raredisease #epdermolysisbullosa #microbiome #dermsky #medsky pubmed.ncbi.nlm.nih.gov/40803690/ 050
Amy Paller, MD @pallerlab.bsky.social · 10/08/2025New review article! Deciding Which Patients With Atopic Dermatitis to Prioritize for Biologics and Janus Kinase Inhibitors doi.org/10.1016/j.ja... #dermsky #medsky 070
Amy Paller, MD @pallerlab.bsky.social · 27/06/2025New Treatments in Atopic Dermatitis Update #DermSky #MedSky @annalsacaai.bsky.social pubmed.ncbi.nlm.nih.gov/40562170/ 061
Amy Paller, MD @pallerlab.bsky.social · 06/05/2025Excited to share that three of our lab members are presenting their work at # #SIDSanDiego25! Come support them at their talks and poster sessions. @siderm.bsky.social #DermSky 061
Amy Paller, MD @pallerlab.bsky.social · 11/04/2025Having a device that can measure TEWL remotely, continuously or as programmed by the investigator - and without perturbing a patient during sleep - is a major advance. #wearabledevices #DermSky A non-contact wearable device for monitoring epidermal molecular flux www.nature.com/articles/s41... 052
Amy Paller, MD @pallerlab.bsky.social · 05/04/2025A new classification of hereditary EDDs highlights shared disease mechanisms—unlocking targeted, pathogenesis-based treatments. From lovastatin-cholesterol to kallikrein inhibitors and gene editing, care for syndromic ichthyosis is evolving. doi.org/10.1093/bjd/... #raredisease #MedSky #DermSky 030
Amy Paller, MD @pallerlab.bsky.social · 28/03/2025Long-term dupilumab treatment in young children (6mo–5y) with moderate-to-severe AD shows low infection rates. This reinforces its strong safety profile for pediatric eczema care. #AtopicDermatitis #Dupilumab #PediatricDermatology #medsky #dermsky Read more: eprints.whiterose.ac.uk/220380/ 030
Amy Paller, MD @pallerlab.bsky.social · 25/03/2025New study on tapinarof cream 1% in pediatric AD! Minimal systemic absorption, favorable safety, and good tolerability in children (2–17 yrs)with extensive AD. The treatment was well tolerated, even on sensitive skin and flexural areas, with only mild folliculitis reported. #atopicdermatitis #dermsky 040
Amy Paller, MD @pallerlab.bsky.social · 09/03/2025Great to be at #AAD2025, sharing our lab’s work and connecting with colleagues in the field. Exciting discussions and a fantastic meeting! Science drives innovation, informs policy, and improves lives—let’s continue to champion its role in society. #StandUpForScience @aadmember.bsky.social 050
Amy Paller, MD @pallerlab.bsky.social · 27/02/2025So proud of our amazing faculty in skin research - consistently at the top and this year #2. Go Northwestern Dermatology! #DermSky #MedSky 030
Reposted by Amy Paller, MDDebra - The Butterfly Skin Charity @debraireland.bsky.social · 25/02/2025Debra and @charitydebra.bsky.social are delighted to support a clinical trial led by @pallerlab.bsky.social @nufeinbergmed.bsky.social. The trial explores #repurposing Dupilumab - used for eczema - to treat itch, blistering, and pain in all types of #EB. Read more 👉 bit.ly/Dupilumabtot... 052
Amy Paller, MD @pallerlab.bsky.social · 15/02/2025Great to see some action in addressing the curtailing of science #MedSky #DermSky #ScienceSky #StandUpForScience2025 0123
Amy Paller, MD @pallerlab.bsky.social · 08/02/2025Excited about a device that both measures scratch based on finger movement and the sound of itch — and can optionally provide a haptic vibration when sensing scratch to stop it, even at night. pubmed.ncbi.nlm.nih.gov/39908036/ 020
Amy Paller, MD @pallerlab.bsky.social · 28/01/2025ISPD Webinar on Neonatal dermatology Saturday, 15 February 8 AM Eastern Standard Time (EST) London: 1 PM | Dubai: 5 PM | Perth: 9 PM Register: www.ispedderm.com/webinar-1-ne... 020
Amy Paller, MD @pallerlab.bsky.social · 26/01/2025Biologics in congenital ichthyosis: are they effective? doi: 10.1093/bjd/ljae420 pubmed.ncbi.nlm.nih.gov/39470394/ "Biologics may lead to improvement in only a subset of patients with congenital ichthyoses with only some of them noting a good response." 020
Amy Paller, MD @pallerlab.bsky.social · 03/12/2024Use of advanced systemic therapy in patients with moderate-to-severe atopic dermatitis in the TARGET-DERM AD Registry pubmed.ncbi.nlm.nih.gov/39623757/ #atopicdermatitis #dermatology 030
Amy Paller, MD @pallerlab.bsky.social · 20/11/2024www.drugdiscoverynews.com/old-drugs-sh... #raredisease #dermatology #ichthyosis 040
